Patient-controlled sedation with propofol in ERCP:alfentanyl vs remifentanyl

• Conditions: Billiar tract and pancreatic disoderes; MedDRA version: 9.1Level: LLTClassification code 10004676Term: Biliary tract disease; MedDRA version: 9.1Level: LLTClassification code 10004677Term: Biliary tract disorder NOS; MedDRA version: 9.1Level: LLTClassification code 10033616Term: Pancreatic disorder

• Registration Number: EUCTR2009-012398-36-FI
• Lead Sponsor: Helsinki University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05-15
• Last Update Posted: 24 November 2014

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

-elective ERCP patients;
-age 18-70
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

-allergy to medcines;
-dementia,mentally handicapped;
-grievous liver or kidneys failure;
-significant heart failure or pulmonary disease

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Main objective of the trial is to compare alfentanyl and remifentanyl in patient-controlled sedation during endoscopic retrograde cholangio-pancreatography.;Secondary Objective: degree of sedation,medcines demand,komplications,recovery time,paine estimation ;Primary end point(s): Pulse,Blood pressure,Oxygen saturation,complications,recovery time